global HTA Decision-Making
The Challenge
Governments around the world are increasingly adopting HTA systems as a way to determine and contain the costs of pharmaceutical therapies. However, in many markets, lack of proper infrastructure, data, capabilities, and resources often hinders well-meaning attempts to increase patient access to medicines while managing healthcare budgets.
Our Solution
Identified three key trends in HTA evolution globally:
An increased interest among governments, payers, academics, and other stakeholders in formalized HTA, including new requirements for pharmacoeconomic (PE) analysis;
Increased cross-country influence and transferability among HTA agencies; and
Stronger collaboration among regional HTA networks in making resource-allocation decisions.
Segmented countries according to whether a formal HTA agency was established and whether PE guidelines were in place. We noted that due to significant differences in emerging countries, adapting a global PE model to regional/local settings may not be appropriate and, ultimately, may lead to patient access to medicines being affected by factors other than evidence of clinical effectiveness.
Based on these findings, a global HTA advocacy plan with recommendations for global, regional, and country-specific strategies based on the implications of these major trends as well as a good understanding of the client’s priorities, was developed.
Benefits to the client
Informed Decision-Making: Equipped with a comprehensive understanding of the potential ramifications of HTA policies, particularly concerning novel and innovative therapies like oncology medicines. This understanding paves the way for strategic insights into optimizing engagements with policymakers and payers across pivotal markets, each at varying stages of HTA evolution.
Empowering Resource Allocation: Enabled the identification of the most effective pathways to empower policymakers and payers within key markets.